Chai Discovery Raises $130 Million for AI Molecule Design
OpenAI-backed biotech firm Chai Discovery has raised $130 million in Series B funding at a $1.3 billion valuation, led by General Catalyst and Oak HC/FT. The company’s Chai-2 platform uses AI to design new antibodies from scratch, improving success rates in drug discovery.